419 related articles for article (PubMed ID: 19661355)
1. Current and future options in the treatment of malignant ascites in ovarian cancer.
Woopen H; Sehouli J
Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
[TBL] [Abstract][Full Text] [Related]
2. [Pathogenesis and management of refractory malignant ascites].
Saâda E; Follana P; Peyrade F; Mari V; François E
Bull Cancer; 2011 Jun; 98(6):679-87. PubMed ID: 21636346
[TBL] [Abstract][Full Text] [Related]
3. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
Ströhlein MA; Heiss MM
Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.
Hirte HW; Miller D; Tonkin K; Findlay B; Capstick V; Murphy J; Buckman R; Carmichael J; Levine M; Hill W
Gynecol Oncol; 1997 Jan; 64(1):80-7. PubMed ID: 8995552
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer.
Gotlieb WH; Feldman B; Feldman-Moran O; Zmira N; Kreizer D; Segal Y; Elran E; Ben-Baruch G
Gynecol Oncol; 1998 Dec; 71(3):381-5. PubMed ID: 9887235
[TBL] [Abstract][Full Text] [Related]
6. Resolution of malignant ascites after intraperitoneal chemotherapy in women with carcinoma of the ovary.
Lind SE; Cashavelly B; Fuller AF
Surg Gynecol Obstet; 1988 Jun; 166(6):519-22. PubMed ID: 3375962
[TBL] [Abstract][Full Text] [Related]
7. [Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report].
Graziosi L; Bugiantella W; Cavazzoni E; Donini A
G Chir; 2009 May; 30(5):237-9. PubMed ID: 19505418
[TBL] [Abstract][Full Text] [Related]
8. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites.
Easson AM; Bezjak A; Ross S; Wright JG
Ann Surg Oncol; 2007 Aug; 14(8):2348-57. PubMed ID: 17505860
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal catheter site metastasis in a patient with advanced ovarian cancer.
Ramirez I; Bansal N; Hoffman M
Am J Hosp Palliat Care; 2012 May; 29(3):241-2. PubMed ID: 21606122
[TBL] [Abstract][Full Text] [Related]
10. [Peritoneal carcinomatosis: new strategies for more efficacious treatment].
Zanon C
Recenti Prog Med; 2002 Sep; 93(9):457-62. PubMed ID: 12355981
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
Hamilton CA; Maxwell GL; Chernofsky MR; Bernstein SA; Farley JH; Rose GS
Gynecol Oncol; 2008 Dec; 111(3):530-2. PubMed ID: 18561992
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report.
Krawczyk M; Zimmermann S; Vidacek D; Lammert F
Onkologie; 2012; 35(10):592-4. PubMed ID: 23038231
[TBL] [Abstract][Full Text] [Related]
13. [What is the value of tumor debulking and intraperitoneal cytostasis].
Laffer U; Knüsli C; Harder F
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():205-10. PubMed ID: 1983552
[TBL] [Abstract][Full Text] [Related]
14. [Study of symptoms in terminally ill patients with ovarian carcinoma].
Sun XG; Wu M; Ma SQ; Li CY; Jin LN; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):192-5. PubMed ID: 17537307
[TBL] [Abstract][Full Text] [Related]
15. Malignant ascites in ovarian cancer and the role of targeted therapeutics.
Smolle E; Taucher V; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1553-61. PubMed ID: 24692682
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery (cs) and hyperthermic intraperitoneal chemotherapy (hipec) in treatment of peritoneal surface malignances: report of a phase II clinical study.
Asero S; Caruso M; Vallone N; Luciani AG; Lombardo V; Terranova G; Ettore G; Giannone G
In Vivo; 2009; 23(4):645-7. PubMed ID: 19567402
[TBL] [Abstract][Full Text] [Related]
17. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.
Tsikouras P; Tsagias N; Pinidis P; Csorba R; Vrachnis N; Dafopoulos A; Bouchlariotou S; Liberis A; Teichmann AT; von Tempelhoff GF
Arch Gynecol Obstet; 2013 Sep; 288(3):581-5. PubMed ID: 23644922
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
Kobold S; Hegewisch-Becker S; Oechsle K; Jordan K; Bokemeyer C; Atanackovic D
Oncologist; 2009 Dec; 14(12):1242-51. PubMed ID: 20008305
[TBL] [Abstract][Full Text] [Related]
19. Palliation of malignant ascites.
Hodge C; Badgwell BD
J Surg Oncol; 2019 Jul; 120(1):67-73. PubMed ID: 30903617
[TBL] [Abstract][Full Text] [Related]
20. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
Berek JS; Edwards RP; Parker LP; DeMars LR; Herzog TJ; Lentz SS; Morris RT; Akerley WL; Holloway RW; Method MW; Plaxe SC; Walker JL; Friccius-Quecke H; Krasner CN
Int J Gynecol Cancer; 2014 Nov; 24(9):1583-9. PubMed ID: 25254563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
